Abstract:Key PointsHypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein that consists of two proteins — HIF-1α and HIF-1β. HIF-1 activates the transcription of many genes that code for proteins that are involved in angiogenesis, glucose metabolism, cell proliferation/survival and invasion/metastasis.HIF-1α protein synthesis is regulated by activation of the phosphatidylinositol 3-kinase (PI3K) and ERK mitogen-activated protein kinase (MAPK) pathways. These pathways can be activated by signalling via receptor tyrosine kinases, non-receptor tyrosine kinases or G-protein-coupled receptors.HIF-1α protein degradation is regulated by O2-dependent prolyl hydroxylation, which targets the protein for ubiquitylation by E3 ubiquitin-protein ligases. These ligases contain the von Hippel–Lindau tumour-suppressor protein (VHL), which binds specifically to hydroxylated HIF-1α. Ubiquitylated HIF-1α is rapidly degraded by the proteasome.HIF-1α is overexpressed in human cancers as a result of intratumoral hypoxia as well as genetic alterations, such as gain-of-function mutations in oncogenes (for example, ERBB2) and loss-of-function mutations in tumour-suppressor genes (for example, VHL and PTEN). HIF-1α overexpression is associated with treatment failure and increased mortality.In xenograft assays, manipulation of HIF-1 activity by genetic or pharmacological means has marked effects on tumour growth because of effects on angiogenesis, glucose metabolism and/or cell survival.Screens are underway to identify small-molecule inhibitors of HIF-1 and to test their efficacy as anticancer agents. These drugs might represent an important component of novel combination therapies that are designed to target signalling molecules in cancer cells.

Small Molecules Targeting HIF-1α Pathway for Cancer Therapy in Recent Years

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

HIF-1α pathway: role, regulation and intervention for cancer therapy

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy

The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy

Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism

Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation

Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer

Central role of hypoxia-inducible factor-1α in metabolic reprogramming of cancer cells: A review

Targeting HIF-1 for cancer therapy

Role of hypoxia in the tumor microenvironment and targeted therapy

Hypoxia-regulated gene network in drug resistance and cancer progression

Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A “structure-activity relationship” perspective

Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

Hypoxia Signaling in Cancer: Implications for Therapeutic Interventions

Natural products as potent inhibitors of hypoxia-inducible factor-1α in cancer therapy

Hypoxia: Intriguing Feature in Cancer Cell Biology